title: Comment on "Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer," i.e., all we are saying is, give C a chance.
authors: Free Radical and Radiation Biology Graduate Program, Department of Surgery, The University of Iowa College of Medicine, Iowa City, IA 52242, USA. joseph-cullen@uiowa.edu
authors: Joseph J
authors: JJ
authors: Cullen
authors: Douglas R
authors: DR
authors: Spitz
authors: Garry R
authors: GR
authors: Buettner
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy*; D000284:Administration, Oral; D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001205:Ascorbic Acid / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004357:Drug Synergism; D006801:Humans; D007275:Injections, Intravenous; D051379:Mice; D010190:Pancreatic Neoplasms / Q000188:drug therapy*; D016896:Treatment Outcome; D000093542:Gemcitabine
chemical_list: D003841:Deoxycytidine; D001205:Ascorbic Acid; D000093542:Gemcitabine